Evidence map›Paper›PMID 24076181›Full record

ArticleEuropean journal of pharmacology2013

Effects of the neurotensin NTS₁ receptor agonist PD149163 on visual signal detection in rats.

Todd M Hillhouse, Adam J Prus

Abstract read
In one paragraph

Article in European journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Todd M HillhouseDepartment of Psychology, Virginia Commonwealth University, Richmond, VA, USA.
Adam J Prus
Northern Michigan University · USVirginia Commonwealth University · US

Funding

Neurotensin Analogs For Neurocognitive Deficits In SchizophreniaR15MH083241 · NIMH · NORTHERN MICHIGAN UNIVERSITY · PI PRUS, ADAM JOSEPH · 2008 to 2009
$207k
NIMH NIH HHS 1R15MH083241-01NIMH NIH HHS R15 MH083241
6 · The paper itself

Abstract

Antipsychotic drugs provide limited efficacy for cognitive impairment in schizophrenia. Recent studies have found that the neurotensin NTS1 receptor agonist and putative atypical antipsychotic drug PD149163 reverses deficits in sensory-gating and novel object recognition, suggesting that this compound may have the potential to improve cognitive functioning in schizophrenia. The present study sought to extend these investigations by evaluating the effects of PD149163 on sustained attention using a visual signal detection operant task in rats. PD149163, the atypical antipsychotic drug clozapine, and the dopamine D2/3 receptor antagonist raclopride all significantly decreased percent "hit" accuracy, while none of these compounds altered "correct rejections" (compared to vehicle control). Clozapine and raclopride significantly increased response latency, while high doses of PD149163 and raclopride significantly increased trial omissions. Nicotine, which was tested as a positive control, significantly improved overall performance in this task and did not affect response latency or trial omissions. The present findings suggest that neurotensin NTS1 receptor agonists, like antipsychotic drugs, may inhibit sustained attention in this task despite having different pharmacological mechanisms of action.

Indexed as

AnimalsAttentionMaleNeurotensinRatsRats, Sprague-DawleyReaction TimeReceptors, NeurotensinVisual PerceptionNeurotensinneurotensin type 1 receptorPD 149163Receptors, NeurotensinAntipsychoticAttentionNeurotensinNTS(1) receptorPD149163Visual signal detection

Identifiers

PMID24076181
PMCPMC3861869
OpenAlexW1985358611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.